26 results about "CXCL10" patented technology

Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.

The invention belongs to the technical field of medicine, particularly relates to application of isodan-leaf emodin in preparation of a CXCL10 inhibitor, and particularly relates to application of the isodan-leaf emodin in treatment of sepsis lung injury, and by establishing a sepsis lung injury model induced by cecum ligation puncture (CLP), the application of the isodan-leaf emodin in preparation of the CXCL10 inhibitor is established. It is proved that the polyphenol monomer drug isodan leaf emodin can significantly improve lung tissue pathological damage, reduce the level of inflammatory factors in lung tissue, inhibit oxidative stress reaction and improve the survival rate of a CLP model. Experiments show that the isodan leaf emodin with the dosage of 25 mg / kg can relieve pulmonary edema and inflammatory response by inhibiting secretion of CXCL10, and a new scheme is provided for treatment of sepsis-related lung injury.

An assay system permits study of cell migration through tissue-relevant extracellular matrices under a chemokine gradient within a modular assay platform. Activated CD3+ T-cells were detected, quantified, and studied as they migrated towards chemokines (CXCL10 and CXCL12) and chemokine mimetics (CXCR3 agonist) using the assay system. Discovery of drugs, and the study of microenvironments, stimuli, and responding cells are facilitated by the assay system.

The invention discloses application of a targeted Nup85 inhibitor in preparation of a medicine for preventing or treating hepatocellular carcinoma, and relates to the technical field of biological medicine and tumor immunotherapy. The invention provides an application of a targeted Nup85 inhibitor in preparation of a medicine for preventing or treating hepatocellular carcinoma. The inhibitor prevents and / or treats hepatocellular carcinoma by enhancing CD8 + T cell functions, enhancement of the CD8 + T cell functions is realized by regulating STAT1 / CCL5 / CXCL10 pathways, and Nup85 reduces expression of CCL5 and CXCL10 by inhibiting nuclear translocation of phosphorylated STAT1, so that infiltration and activation of CD8 + T cells are inhibited. The invention discloses an immune escape mechanism that Nup85 inhibits CD8 + T cell infiltration by inhibiting p-STAT1 nuclear translocation and down-regulating CCL5 / CXCL10 expression in liver cancer for the first time, provides a new liver cancer immunotherapy target, and broadens the application of nucleopore protein in tumor immunotherapy; the target Nup85 inhibitor can be obtained through a conventional means, a new clinical application direction of the target Nup85 inhibitor is defined, and the target Nup85 inhibitor has good clinical transformation and development prospects.

The present invention provides: an oncolytic virus such as a conditionally replicating adenovirus carrying the CXCL10 gene; the oncolytic virus additionally carrying the IL-2 gene and / or the GM-CSF gene on the same viral genome; a combination of the oncolytic virus and a separate oncolytic virus carrying the IL-2 gene and / or the GM-CSF gene; and a cancer treatment agent comprising any of the aforementioned oncolytic viruses or a combination thereof as an active ingredient.

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and their use in methods of detecting and / or diagnosing a condition in a subject, including determining the level of CXCL10 in a subject. Specific antibodies that bind total CXCL10 (full length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full length) are used to measure the level of total CXCL10 and active CXCL10 in ovarian cancer patient samples. The calculated ratio between active CXCL10 and total CXCL10 is lower in patients with malignant disease compared to patients with benign tumors or healthy individuals, and this calculated ratio is the basis for methods of diagnosing malignant disease, monitoring tumor burden and disease progression.

The invention provides an application of a MAT2A inhibitor in preparation of a medicine for preventing and / or treating inflammation. A cell experiment result shows that the MAT2A inhibitor has a remarkable inhibition effect on an inflammatory cell model after administration, and mRNA expression levels of various inflammatory factors TNF-alpha, IFN-gamma, IL-1beta, IL-6, IL-12a and CXCL10 in cells are remarkably reduced; the invention provides a new direction for treating inflammatory diseases.

The invention relates to an application of a cytokine CXCL10 in depression and / or anxiety disorder. Specifically, the inventor verifies that the cytokine CXCL10 can effectively treat depression and / or anxiety disorders.

The invention relates to the technical field of biological medicine, and discloses a medicine composition for promoting anti-tumor immunity and application of the medicine composition in preparation of medicine for treating tumors, the medicine composition comprises small molecules and a PD-1 antibody, and the small molecules have the following structure: # imgabs0 #. The micromolecule obtained by the invention can target REXO4 enzyme and inhibit the enzyme activity of the REXO4 digestion R-loop structure, so that the increase of the R-loop structure of tumor cells is promoted, and the purposes of promoting infiltration of anti-tumor immune cells and inhibiting tumor growth are achieved. The small molecule can promote generation of I-type interferon related chemotactic factors Cxcl10 of tumor cells, so that recruitment of anti-tumor related immune cells is caused, an immune checkpoint inhibitor therapy is enhanced, and the aim of killing the tumor cells is achieved.

The application belongs to the technical field of biological medicine, and particularly relates to the use of SH2 domain-containing protein tyrosine phosphatase 1 (SHP1) in the preparation of a drug for treating chronic pain, in particular to the use of SHP1 in the preparation of a drug for treating chronic pain by regulating the morphology of spinal cord astrocytes, the integrity of the blood-spinal cord barrier and the STAT1-CXCL10-CXCR3 neuroimmune signal axis, and a chronic pain treatment strategy based on the signal axis. The application first discloses that SHP1 in spinal cord astrocytes directly dephosphorylates STAT1, inhibits the transcription of CXCL10 and the subsequent infiltration of T lymphocytes into the spinal cord, and discloses the core analgesic mechanism, thereby establishing SHP1 as a new target for treating chronic pain, and opening up a new way for the precise treatment of clinical chronic pain, especially neuropathic pain.

A MASH biomarker composition and an application thereof is provided, the biomarker composition including a protein marker and / or clinical biochemical marker for the diagnosis of MASLD and / or MASH, the protein marker being selected from CXCL10, CK-18, P62 / SQSTM1, CA3, SQLE, Pro-C3 or one or more of FGF21; the clinical biochemical marker is selected from one or more of BMI, HDL-C, HbA1c, ALT, AST, LDL-C, TG, TC, ALP, or PLT. Biomarker compositions were established by logistic regression and artificial intelligence methods as diagnostic markers for the diagnosis of MASLD and MASH with high sensitivity, specificity, positive predictive value, and negative predictive value in the diagnosis of MASH, independent of age, gender, or metabolic status.

Provided herein are methods and immune biomarkers for identifying multiple sclerosis (MS) progression and treatment options. Materials and methods for prognosing, staging, and monitoring MS in a sample are also provided, including methods for determining a subject as at risk for developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of a subject, and administering a pharmaceutically effective amount of a therapy (e.g., trebrutinib and potentially one or more additional therapies, e.g., an anti-CD20 therapy) to the subject.

Provided herein are methods and immune biomarkers for identifying progression and therapeutic selection of multiple sclerosis (MS). Also provided are materials and methods for prognosis, staging, and monitoring of MS in a sample, and including methods of determining that a subject is at risk of developing MS. The method comprises detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of the subject; and administering to the subject a pharmaceutically effective amount of a treatment (e.g., tobutinib and potentially one or more additional therapies, such as an anti-CD20 therapy).

Provided are an engineered immune cell expressing CXCL10 and IL15 and the use thereof. The immune cell can further express a chimeric antigen receptor or a T cell receptor. The engineered immune cell can enhance the recruitment and accumulation of immune cells, enhance the killing efficiency of immune cells on target cells, and enhance the treatment effect of immune cells on tumors, such as solid tumors.

The invention provides a system for identifying whether a person is in an active tuberculosis infection state or not from gene expression of peripheral blood and application of the system, and the system is used for simultaneously detecting expression levels of human FCGR1A gene, FCGR1B gene, GBP5 gene, GBP6 gene, CXCL10 gene and KLF2 gene so as to determine whether the person is in the active tuberculosis infection state or not. The sensitivity of combined detection of the six genes is 91.18%, the specificity reaches 86.84%, the target requirement for terminating tuberculosis in 2035 published by the United National Health Organization is met, and TB high-risk groups can be screened out by the method and then diagnosed by a diagnosis method.

The invention provides application of a PD-1 inhibitor to preparation of a medicine for treating prostatic cancer with TP53 gene mutation, and relates to the technical field of medicine. The medicine comprises a therapeutically effective amount of the PD-1 inhibitor and a pharmaceutically acceptable carrier auxiliary component thereof. The PD-1 inhibitor and Mutp53 are related to epithelial lineage, metabolic reprogramming and recombination of CAF and immune cell population, so that the improvement of tumor immunity accessibility is promoted together. In a comprehensive view, the discovery reveals a direct mechanism relation among TP53 high-frequency mutation, Cxcl10 signal transduction and ICB treatment sensitivity, and a new biological insight and a potential strategy are provided for layering and combined treatment of patients suffering from CRPC.

The present invention relates to the use of cytokine CXCL10 in depression and / or anxiety disorders.

The present application provides a system for identifying whether a person is in an active tuberculosis infection state from gene expression of peripheral blood and application thereof, the system is used for simultaneously detecting expression levels of FCGR1A gene, FCGR1B gene, GBP5 gene, GBP6 gene, CXCL10 gene and KLF2 gene, so as to determine whether the person is in an active tuberculosis infection state. The sensitivity of the 6-gene combined detection of the present application is 91.18%, and the specificity reaches 86.84%, which meets the requirements of the goal of ending tuberculosis by 2035 published by the World Health Organization, and the method of the present application can screen out high-risk TB population, and then use a diagnosis method for diagnosis.

Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity, including against multidrug-resistant bacteria. In some embodiments, the peptides include amino acid sequences as set forth in any of SEQ ID NOs: 2-151, modified peptides, fragments, and conjugates thereof, and any combination thereof. The peptides, modified peptides, fragments, and conjugates can be polymer-functionalized, encapsulated in a particle, embedded in and / or on a solid support, impregnated in a dressing, and / or is formulated for use in a nebulizer, for topical administration, and / or for systemic administration. Also provided are medical devices having an antibacterial agent embedded in and / or associated with a support layer, and methods for inhibiting growth of and / or killing bacteria, for treating or preventing community and / or nosocomial infections, for treating bacterial infections present in wounds, for treating pulmonary infections, for treating or preventing systemic bacterial infections, and for combination therapies with conventional antibiotics.

The present invention relates to a method for determining a transcriptome score (TScore) suitable for assessing the risk of an undesirable clinical outcome of a patient in a clinical environment from an assay sample or population of assay samples previously extracted from the patient, the method comprising, among other steps, determining a transcriptome score (TScore) suitable for assessing the risk of an undesirable clinical outcome of the patient, gene expression values of at least two different genes selected from a predetermined set of genes are measured for a patient sample or a population of samples previously obtained from the patient, and a transcriptome score is determined, where the genes are assigned or not assigned scores. The method may be computer implemented. The genes of the predetermined set of genes may be at least two genes selected from the group consisting of ADGRE3, ARL14EP, BPGM, C3AR1, CCNB1IP1, CD177, CD274, CD3D, CD74, CIITA, CTLA4, CX3CR1, GNLY, IFNgamma, IL10, IL1R2, IL1RN, IL7R, IP10 / CXCL10, MDC1, OAS2, S100A9, TAP2, TDRD9, TNF, and ZAP70. The method may be performed on an assay biological sample extracted from a patient who has been treated in a resuscitation department, an intensive care unit, or a continued care unit. The invention also relates to a method of classifying samples previously taken from a patient as a group reflecting the risk of an undesirable clinical outcome in a clinical environment, or a method of identifying a patient at risk of an undesirable clinical outcome in a clinical environment, and an in vitro or ex vivo method of screening for whether a drug has the ability to alleviate an undesirable clinical outcome in a patient. The invention also relates to a computer device for carrying out the invention, and to the use of a kit for carrying out the method of the invention.

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof. The present invention also relates to methods of detecting and / or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject.

The invention provides a specific primer and probe for detecting bovine tuberculosis and a kit composed of the specific primer and probe, and belongs to the technical field of biological detection. Specific primer pairs and probes are designed for cattle CXCL10, IFN-gamma and GAPDH genes, and quantitative detection of the transcription level of CXCL10 and IFN-gamma in cattle in-vitro whole blood is realized by using a qPCR technology, so that cattle tuberculosis is diagnosed. The method greatly shortens the detection time (incubation only needs 4 hours), simplifies the operation process, eliminates the system error in the sample adding process by using the GAPDH gene as the internal reference, and improves the accuracy of the detection result.

Disclosed herein are methods of diagnosing a subject for a risk of developing severe coronavirus disease as correlated to the presence of IgA anti-IFN-alpha autoantibodies. In certain embodiments, the methods include the use of fluorescent beads that are used to analyze the presence of IgA1 and / or IgA2 anti-IFN-alpha autoantibodies and simultaneous measurement of IFN-α and CXCL10 in the same nasal sample. In certain embodiments, methods further comprise reporting the diagnosis to the subject or medical professional. In certain embodiment, methods further comprise administering a pharmaceutical agent to the subject.

The present invention provides methods, assays and kits for evaluation and assessment of IP-10 (CXCL10) expression, particularly IFN induction of IP-10, to determine the presence of inborn errors of the Type I IFN or Type II IFN response pathway and / or auto-antibodies directed against, and particularly neutralizing, Type I IFNs or Type II IFNs in a patient. The methods, assays and kits including for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine-associated disease and adverse events, and for evaluation, treatment and management of patients, particularly including those who develop vaccine-associated disease. Identification of inborn errors of the Type 1 IFN response pathyway and / or auto-antibodies directed against, and particularly neutralizing, Type I IFNs are associated with severe viral illness, including COVID-19 disease, and vaccine-associated disease, particularly with live attenuated virus vaccines, particularly including yellow fever vaccines, as well as arboviral diseases, including WNV and TSE encephalitis.

The present invention provides: an oncolytic virus such as a conditionally replicating adenovirus carrying the CXCL10 gene; the oncolytic virus additionally carrying the IL-2 gene and / or the GM-CSF gene on the same viral genome; a combination of the oncolytic virus and a separate oncolytic virus carrying the IL-2 gene and / or the GM-CSF gene; and a cancer treatment agent comprising any of the aforementioned oncolytic viruses or a combination thereof as an active ingredient.